Jade Biosciences, Inc. JBIO

US Biotechnology
$15.92 โ–ฒ +2.05% (+$0.32)
🔥 High Short Interest 📅 Earnings This Week
Open $15.59
Prev Close $15.60
Day Range $15.26 โ€“ $15.97
52W Range $8.36 โ€“ $28.00
Market Cap $992.12M
Beta 1.82
EPS (TTM) $-2.84

๐Ÿ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2021-06-30
Shares Out.63,600,000
Websitejadebiosciences.com โ†—
Phone17813123013
Employees55
Revenue$0
Gross Profit$0
Net Income-$55.8M
Free Cash Flow-$110.2M
Total Assets$472.1M
Total Liabilities$32.2M
Equity$439.9M
About Jade Biosciences, Inc.

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Jade Biosciences, Inc. is a publicly traded company under the ticker symbol JBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

๐Ÿ“Š Analyst Ratings

17 analysts (2026-11-01)

Strong Buy 8
Buy 8
Hold 1

๐Ÿ“ฐ Latest News for JBIO

๐Ÿ‘ฅ Related Stocks